157 related articles for article (PubMed ID: 8522350)
21. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.
Kogelberg H; Tolner B; Sharma SK; Lowdell MW; Qureshi U; Robson M; Hillyer T; Pedley RB; Vervecken W; Contreras R; Begent RH; Chester KA
Glycobiology; 2007 Jan; 17(1):36-45. PubMed ID: 17000699
[TBL] [Abstract][Full Text] [Related]
22. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
23. A large-scale purification of beta-glucuronidase from human liver by immunoaffinity chromatography.
Ho KJ
Biotechnol Appl Biochem; 1991 Dec; 14(3):296-305. PubMed ID: 1777114
[TBL] [Abstract][Full Text] [Related]
24. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
25. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
[TBL] [Abstract][Full Text] [Related]
26. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
Fang L; Sun D
Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
[TBL] [Abstract][Full Text] [Related]
27. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
de Graaf M; Boven E; Oosterhoff D; van der Meulen-Muileman IH; Huls GA; Gerritsen WR; Haisma HJ; Pinedo HM
Br J Cancer; 2002 Mar; 86(5):811-8. PubMed ID: 11875747
[TBL] [Abstract][Full Text] [Related]
28. Antibody-enzyme conjugates for cancer therapy.
Melton RG; Sherwood RF
J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
[TBL] [Abstract][Full Text] [Related]
29. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
[TBL] [Abstract][Full Text] [Related]
30. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
31. Purification and immunological quantification of rat liver lysosomal glycosidases.
de Groen PC; LeSage GD; Tietz PS; LaRusso NF
Biochem J; 1989 Nov; 264(1):115-23. PubMed ID: 2513804
[TBL] [Abstract][Full Text] [Related]
32. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
34. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Wallace PM; Senter PD
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
[TBL] [Abstract][Full Text] [Related]
35. Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing.
Gingis-Velitski S; Ishai-Michaeli R; Vlodavsky I; Ilan N
FASEB J; 2007 Dec; 21(14):3986-93. PubMed ID: 17628014
[TBL] [Abstract][Full Text] [Related]
36. Specific monoclonal antibody against human trypsin.
Acosta Bas C; Baluja Conde IB; Brito Moreno AI; Rodriguez Lopez MR; Melchor A; Hernandez L; Frómeta A
Hybrid Hybridomics; 2002 Aug; 21(4):307-10. PubMed ID: 12193285
[TBL] [Abstract][Full Text] [Related]
37. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Springer CJ; Poon GK; Sharma SK; Bagshawe KD
Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
[TBL] [Abstract][Full Text] [Related]
38. Development and optimization of an enzyme-linked immunosorbent assay employing two murine monoclonal antibodies for absolute quantitation of human beta-glucuronidase.
Ho KJ
Biotechnol Appl Biochem; 1992 Aug; 16(1):1-10. PubMed ID: 1418687
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
40. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
